This week’s glioblastoma news ranges from early lab science to hard trial results to real stories of people living well past their original prognosis. Here’s what’s worth knowing:

A B12-Based Molecule Shows Early Promise in Mice

Researchers have engineered a compound based on vitamin B12 that can slip across the blood–brain barrier — the body’s tight security checkpoint that normally keeps most drugs out of the brain. In mouse studies, the compound built up inside glioblastoma tumors and appeared to help the immune system go after the cancer. This is still animal-stage research, not yet tested in people.

Why it matters: Glioblastoma is notoriously hard to treat partly because so few drugs can get past the blood–brain barrier, and the standard of care has barely changed since the 1970s. A compound that can sneak past that barrier and wake up the immune system is a genuinely exciting direction for science — but it’s early days. This is mouse data, not a clinical trial, so it could be years (if ever) before something like this reaches patients. Worth watching, not worth pinning hopes on yet.

Source: ScienceDaily — sciencedaily.com

A Major Trial Combining Treatments Didn’t Extend Survival

A large Phase 3 trial called TRIDENT tested whether adding Tumor Treating Fields — a wearable device that uses electrical fields to interfere with cancer cell division — earlier in treatment, alongside chemotherapy and radiation, would help people newly diagnosed with glioblastoma live longer. The trial missed its main goal: it didn’t improve overall survival. The approach was still safe and tolerable for patients.

Why it matters: Negative trial results aren’t fun to read, but they matter just as much as positive ones — they tell doctors and researchers what doesn’t work, so resources and hope can be redirected. If you or someone you love uses or is considering Tumor Treating Fields, this result is specifically about starting it earlier alongside chemoradiation, not about the device’s broader use, so it’s worth talking through with your care team rather than reading too much into the headline alone.

Source: Targeted Oncology — targetedonc.com

Survive Two Years, and the Odds Start Tilting Your Way

A look at survival data from more than 52,000 adults with glioblastoma found that the longer someone lives past diagnosis, the better their odds of continuing to survive get. The chance of living another year rose from 40% right at diagnosis to 57% for people who had already made it to the two-year mark.

Why it matters: Statistics like these don’t change anyone’s individual situation, but they offer something real: hope that’s grounded in data, not just sentiment. For patients and families living past the early, scariest stretch after diagnosis, this is a reminder that survival odds aren’t fixed — they shift in your favor the longer you’re here. It won’t feel like much comfort in the first hard year, but it’s a number worth holding onto if you make it to year two.

Source: Vera Health — verahealth.ai

A Tiny Implant in the Skull Could Help Drugs Reach Brain Tumors

The NIH has awarded up to $4 million to CraniUS Therapeutics to develop NeuroPASS, a refillable device implanted directly in the skull that's designed to deliver medication straight into brain tissue, bypassing the blood-brain barrier that normally blocks most drugs from reaching the brain. The device has a hidden refill port so doses could potentially be topped up during routine outpatient visits. It's still investigational and hasn't been tested in people yet, but the funding will support work toward a first-in-human study in recurrent glioblastoma.

Why it matters: Getting drugs past the blood-brain barrier is one of the biggest obstacles in treating glioblastoma, and a device built to solve that problem head-on is a meaningful direction, especially for recurrent GBM, where typical survival after recurrence is only six to nine months. That said, this is still device development funding, not a treatment available today — there's no human safety or effectiveness data yet, and "first-in-human study" likely means years before this could reach patients, if it gets there at all.

Source: BioSpace — https://www.biospace.com/press-releases/nih-awards-up-to-4-million-to-cranius-therapeutics-to-advance-skull-embedded-platform-designed-to-bypass-the-blood-brain-barrier

Antiques Roadshow’s Theo Burrell Marks Four Years — Triple Her Original Prognosis

Theo Burrell, an expert on the BBC’s Antiques Roadshow, shared that she recently passed four years since her glioblastoma diagnosis in June 2022. She was originally told to expect 12 to 18 months to live; instead she is marking year four and says, “I will not give up.”

Why it matters: Prognosis numbers are averages, not guarantees, and Theo’s story is a real, public example of that gap. For patients and caregivers drowning in statistics right after a diagnosis, stories like hers don’t erase how serious glioblastoma is, but they’re a genuine reminder that individual outcomes vary, sometimes by years. It’s okay to hold both truths at once: the disease is hard, and outliers are real.

Source: Manchester Evening News — manchestereveningnews.co.uk

A Son in England Turned His Mom’s Diagnosis Into a Brain Tumor Research Fund

An entrepreneur in Henley, England launched a new sports brand after his mother was diagnosed with glioblastoma, with proceeds from sales going toward brain tumor research.

Why it matters: Most glioblastoma research funding doesn’t come from big institutional budgets alone — it leans heavily on grassroots efforts like this one, started by people with direct, personal stakes. Stories like this are a small but real reminder that the GBM community keeps showing up for itself, turning grief and fear into something that funds the next round of research.

Source: Oxford Mail — oxfordmail.co.uk